Background: Subcutaneous injection route (SCIT) is burdened with the risk of severe adverse events; therefore, sublingual immunotherapy (SLIT) is being increasingly investigated. The efficacy of SLIT in asthma has been reviewed in a Cochrane meta-analysis. Allergic sensitization to Dermatophagoides pteronyssinus (Dp), Dermatophagoides siboney (Ds) and Blomia tropicalis (Bt) is strongly linked to respiratory allergy and asthma in Cuba (3). These last 2 species are relevant in tropical countries or even only in the Caribbean region (4). Nevertheless, well conducted clinical studies of immunotherapy with standardized allergen vaccines of these particular species are very scarce. Objective: This study was conducted to assess the therapeutic effect and safety of allergen therapeutic vaccines of Dermatophagoides pteronyssinus, Dermatophagoides siboney and Blomia tropicalis House-Dust mites (VALERGEN, BIOCEN, Cuba) by sublingual route, in asthmatic patients. Methods: Three Double-Blind Placebo-Controlled clinical trials were performed in 40 patients each, showing asthmatic symptoms and positive predominant Skin Prick Test (SPT) to each mite, respectively. Half of subjects were randomized to active group. Treatment consisted of sublingual drops with increasing daily doses for 3 weeks and maintenance doses (2000 BU) twice a week until 12 months. Results: Therapeutic effect was assessed after 6 and 12 months using symptoms/medication diary cards, peak expiratory flow (PEF) measures and skin sensitivity to investigated mites. Adverse reactions were classified using the World Allergy Organization scale. The treatment reduced significantly (P , 0.01) clinical symptoms (38%, 95% CI, 33-44) and medication intake (26%, 95% CI, 21-32) with respect to placebo. The skin sensitivity to the allergens decreased also significantly (P , 0.01). The allergen amount needed to induce a positive SPT increased 52-fold. PEF variability decreased also significantly (P , 0.05). The treatment was considered effective in 77% of patients. A major advantage as compared to subcutaneous route was a remarked lower frequency of adverse effects. Local reactions were noted only in 0.43% of administrations. No systemic reactions were observed.
Results: The final sample size included 88 subjects for on-treat analysis (SLIT; N ¼ 51, placebo; N ¼ 37) for the DBPC study, and a total of 63 patients completed a pollinosis-symptom diary for the single-blind follow-up study (SLIT; N ¼ 36, placebo; N ¼ 27). The symptom-medication score (SMS) in the SLIT group did not differ from that in the placebo group in the 2007 peak pollen season. However, the average SMS in 2008 and 2009 peak pollen seasons were significantly ameliorated in the SLIT group compared with the placebo group (4.2 vs. 5.3, P ¼ 0.02 in 2008; 3.5 vs. 4.5, P ¼ 0.03 in 2009). The ratio of Japanese cedar pollen-specific IgE to total IgE before treatment correlated with the SMS in the SLIT group in 2008. The patients with increased Cry j 1-specific iTregs in the SLIT group showed a significant reduction of QOL and QOL-symptom scores compared with those in the placebo group. Conclusions: SLIT can ameliorate the clinical symptoms after 2-year administration with standardized extract of Japanese cedar pollen and the amelioration was observed for at least one pollen season after the treatment. The ratio of specific IgE to total IgE can be used as a prognostic biomarker and the increase of Cry j 1-specific iTregs may serve as a biomarker to monitor the clinical response to SLIT. 
